Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Initiation
  • Large Cap
  • News
  • Price Target

Weight Loss Drugs – Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst

By Vandana Singh
December 1, 11:55 AM
Cantor Fitzgerald has initiated coverage on Europe's most valuable company, Novo Nordisk A/S (NYSE: NVO).

LLY

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Why Is Chronic Disease Focused Biora Therapeutics Stock Trading Higher Today?

By Vandana Singh
December 1, 11:01 AM
Biora Therapeutics Inc (NASDAQ: BIOR) announced that the FDA has cleared the company's Investigational New Drug (IND) application for BT-600, a drug/device combination for moderate to 

BIOR

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Tale Of Two Investigational Obesity Drugs: Altimmune Stock Jumps, While Pfizer Trades Lower

By Vandana Singh
December 1, 10:06 AM
Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide 

ALT

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

This Twice Daily Weight Loss Drug Has Adverse Side Effects And Pfizer Wants To Discontinue It

By Vandana Singh
December 1, 9:15 AM
Pfizer Inc (NYSE: PFE) reported topline data from the Phase 2b trial investigating its oral weight loss drug Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. 

PFE

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits

By Vandana Singh
December 1, 8:48 AM
AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE-

AZN

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News
  • Trading Ideas

Competition and Optimism: GSK’s CEO Walmsley Foresees Growth Despite Competition In RSV Vaccine Market

By Vandana Singh
November 30, 3:15 PM
Emma Walmsley, the Chief Executive Officer of GSK plc (NYSE: GSK), expressed confidence in its respiratory syncytial virus (RSV) vaccine, Arexvy, anticipating sales to surpass £1 billio

GSK

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Why Is This Rare Disease-Focused Soligenix Stock Trading Over 200% Today?

By Vandana Singh
November 30, 1:07 PM
The FDA has cleared Soligenix Inc's (NASDAQ: SNGX) Investigational New Drug (IND) application for a Phase 2a clinical trial for SGX945 (dusquetide) for aphthous 

SNGX

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • M&A
  • Movers
  • News
  • Trading Ideas

ImmunoGen’s Flagship Cancer Therapy Draws AbbVie’s Attention With $10.1B Deal

By Vandana Singh
November 30, 12:30 PM
AbbVie Inc (NYSE: ABBV) has agreed to acquire ImmunoGen Inc (NASDAQ: IMGN) and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved f

ABBV

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient

By Vandana Singh
November 30, 12:09 PM
Novo Nordisk A/S (NYSE: NVO) has reportedly taken legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their products claiming to contain the active ingredient, semaglutide, for its popular 

LLY

Read More
1 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Management
  • Markets
  • Movers
  • News

Why Is Eagle Pharmaceuticals Stock Trading Lower Today?

By Vandana Singh
November 29, 2:46 PM
Eagle Pharmaceuticals Inc's (NASDAQ: EGRX) Scott Tarriff, founder, president, and Chief Executive Officer, announced his resignation and retirement, 

EGRX

Posts pagination

Previous 1 … 108 109 110 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service